CDKN2A and Miyoshi myopathy: We further analyzed 239 MM patients pooled in 4 studies and found there is no significant difference between the level of the p16 hypermethylation in stage III and stage I, OR=0.52, CI=0.24-1.16, p=0.11, as presented in Figure 3B.